Skin Treatments Introduced in 2016

The list covers new skin treatments for Actinic Keratosis, Hemangioma, Hidradenitis Suppurativa, as well as Anti-acne Agents, Antibacterial Agents, Anti-cancer Agents, Dermal Fillers, Neuromodulator and other treatments and drugs.

Plasma Skin Regeneration Technology

Plasma skin regeneration technology uses energy delivered from plasma rather than light or radiofrequency. Plasma skin regeneration technology can be used at varying energies for different depths of effect, from superficial epidermal sloughing to deeper dermal heating.

The Dermatology Dispensing Debate

The in-office dispensing of topical skin care products by dermatologists is a source of frequent debate. Guidelines for proper dispensing have been penned by various medical organizations, yet the controversy continues. With the increasing number of physician-dispensed lines available for sale, combined with mounting medical financial issues, the ongoing debate surrounding in-office dispensing will continue.

Update on Drugs and Drug News – February 2008

Update on Anti-psoriatic Agent Ustekinumab CNTO 1275, Anti-arthritic Agent Tocilizumab Actemra®, Neurotoxin Botulinum Toxin Type A Reloxin®, and news from The National Institute for Health and Clinical Excellence (NICE) in the UK.

Update on Drugs and Drug News March 2005

Update on: Alefacept AMEVIVE® Dapsone Gel 5% Aczone® Nitroglycerin Ointment Cellegesic® Cefdinir Oral Suspension Omnicef® Ultrasonic Skin Permeation Device SonoPrep® Tazarotene Capsules

A Controversial Proposal: No More Antibiotics for Acne!

Administration of antibiotics, often for prolonged periods, has become the standard of care for acne. The authors provide current evidence to suggest that dermatologists should consider a departure from standard operating procedure by curtailing, if not discontinuing, the routine and regular use of antibiotics for acne.

Promising Therapies for Treating and/or Preventing Androgenic Alopecia

Androgenetic alopecia (AGA) may affect up to 70% of men and 40% of women at some point in their lifetime. Here we briefly review current therapeutic options and treatments under active investigation.

Off-label (unlabeled) Use of Drugs

Some of the most striking advances in dermatology have followed the off-label use of drugs. This review examines some of the issues surrounding off-label use of drugs by dermatologists, illustrates the need for such use and looks at possible changes in the regulatory system.

Update on Drugs and Drug News: November-December 2013

Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)

Treatments for Scalp Psoriasis with Emphasis on Calcipotriol Plus Betamethasone Dipropionate Gel (Xamiol®)

Scalp psoriasis occurs in 50%-75% of patients with plaque psoriasis. It may be the only area of the body affected, or it may be associated with disease elsewhere, including psoriatic arthritis. Most cases are treated topically, usually with steroids and/or calcipotriol.

Alefacept Treatment for Chronic Plaque Psoriasis

Biologic agents were introduced during the past decade as a new class of treatments for chronic psoriasis. This review will discuss data from clinical trials that have provided new insights into the efficacy, safety, and cost effectiveness of alefacept as a treatment for psoriasis.

Update on Drugs & Devices: January – February 2020

This update covers Lebrikizumab SC injection (Dermira), Infliximab-axxq for IV injection (Avsola™, Amgen), Trifarotene cream 50 mcg/g (Aklief®, Galderma), Adalimumab-afzb for SC injection (Abrilada™, Pfizer), Lidocaine + tetracaine (7%/7%) local anesthetic cream (Pliaglis®, Crescita Therapeutics), Maralixibat oral solution (Mirum Pharmaceuticals), Cetirizine hydrochloride for IV injection (Quzyttir™, TerSera Therapeutics) and Minocycline foam 4% (Amzeeq™, Foamix)

Update on Drugs and Drug News – July-August 2006

Update on Zoster Vaccine Live Zostavax®, Doxycycline, 40mg Oracea®, Hyaluronic Acid Dermal Filler Juvéderm® Gel, Mycophenolate Mofetil CellCept®, Suberoylanilide Hydroxamic Acid (SAHA) Zolinza®, Quadrivalent Human Papillomavirus Recombinant Vaccine Gardasil®, and Adalimumab Humira®.

Update on Drugs and Drug News: September-October 2015

Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)

Update on Drugs & Devices: May-June 2022

This update covers Nivolumab + Relatlimab-rmbw for IV use - Opdualag™ (Bristol-Myers Squibb), Sirolimus topical gel 0.2% - Hyftor™ (Nobelpharma America), Oral epinephrine - AQST-109 (Aquestive Therapeutics), and Bimekizumab for SC use - Bimzelx® (UCB Canada Inc.).

Update on Sunscreens

Sunscreens have been around for more than 70 years. This article will review some of the recent advances in photoprotection, including the development of sunscreen formulations offering higher and broader protection against solar radiation.

Dupilumab for Moderate-to-Severe Atopic Dermatitis

Despite a rising prevalence, effective and safe therapeutics for patients with moderate-to-severe AD are limited due to toxicity and side effects. Dupilumab, an interleukin (IL)-4 and IL-13 antagonist that limits type 2 T helper (Th2) driven inflammatory activity, is a promising therapeutic option.

Hydrogen Peroxide Topical Solution, 40% (w/w) for the Treatment of Seborrheic Keratoses: A Review

Given our current options for the treatment of Seborrheic Keratoses include only more invasive, non-topical therapies, Hydrogen Peroxide Topical Solution (40%) fills a void in our therapeutic repertoire as the first FDA-approved topical therapy for SKs.

Update on Drugs & Devices: September – October 2019

The latest drug & device update covers: Adalimumab-bwwd for SC injection (Hadlima™), Apremilast tablets (Otezla®), Calcipotriene + betamethasone dipropionate (Enstilar® foam Taclonex® topical suspension), Bempegaldesleukin + nivolumab for IV use (NKTR-214 + Opdivo®), Dupilumab for SC injection (Dupixent®), Magnetic muscle stimulation for body contouring (CoolTone™), Laser device for body contouring (eon™ FR).

Face-Lifting: An Overview

Numerous adaptations of face-lift techniques have been devised, and each surgical approach has its own risks and benefits, as well as proponents and detractors. All of the conventionally accepted techniques achieve removal of redundant skin.

Botulinum Toxin Type A: New Information about an Old Medicine

Several formulations of botulinum toxin type-A (BoNT-A) are on the market in North America. This article discusses formulations, and differences in pharmacokinetics, and how it affects indications.

The Health Controversies of Parabens

It is hypothesized that the estrogenic properties of parabens may play a role in breast cancer development. At this point, there is an insufficient amount of data suggesting serious consequences from paraben use and exposure to warrant drastic avoidance measures or government regulations.

Imiquimod: An Immune Response Modifier

Imiquimod is an immune response modifier. Studies have shown that it has potent immunomodulatory effects and stimulates human peripheral mononuclear cells to release interferon alpha, sub-types α1,α2, α5, α6, and α8.

Recent Approval of Xerese in Canada: 5% Acyclovir and 1% Hydrocortisone Topical Cream in the Treatment of Herpes Labialis

Herpes labialis is a frequently occurring viral infection of the lips and oral mucosa. Clinical data on the efficacy of topical combination acyclovir-hydrocortisone (Xerese™) product in treating herpes labialis are discussed.

Oral Lichen Planus: Treatment Options

Estimates of the percentage of patients with cutaneous lichen planus (LP) who also have oral LP vary from somewhere between a third and a half 1-3, to as high as 70% and even higher when the cutaneous lesions are of long duration.

Alternative Treatments For Atopic Dermatitis: A Selected Review

Herbal remedies are largely unregulated, but often talked about among patients. Many may have scientific merit and clinical benefit, but they are still scientifically invalid and inadequately monitored. Dermatologists need information about herbal remedies to better serve their Atopic Dermatitis patients.

Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa

Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Discussion includes, safety and efficacy in clinical trials.

US FDA Advisory Committee Meetings Held to Discuss Isotretinoin, Safety Issues and a New Accutane Formulation

There is no drug that has provided as much therapeutic benefit for 12 million acne patients as this retinoid has done in the past 18 years following its introduction. However, it is a retinoid and, therefore, a teratogen.

Age-related Percutaneous Penetration Part 1: Skin Factors

Changes in the skin that occur in the elderly may put them at increased risk for altered percutaneous penetration from pharmacotherapy along with potential adverse effects. This overview discusses the current data of studies to evaluate the impact of skin factors in age-related percutaneous penetration.

The Role of Cosmeceuticals in Antiaging Therapy

As baby boomers get older, they have shown an increasing interest in maintaining a youthful appearance. This paper reviews the more common cosmeceutical ingredients.

Dermatitis Herpetiformis

Dermatitis herpetiformis is an autoimmune, pleiomorphic, papulovesicular disorder associated with celiac disease and gluten sensitivity. This article will provide a comprehensive review of Dermatitis herpetiformis, including its epidemiology, clinical and pathological findings, diagnostic evaluation, and management.

Interleukin-17 (IL-17) Inhibitors in the Treatment of Plaque Psoriasis: A Review

Interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. This article reviews efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) for the treatment of plaque psoriasis.

Update on Drugs and Drug News: March 2012

Update on drugs, approval dates, and comments. Ingenol mebutate gel (0.015%, 0.05%) Picato® and Vismodegib capsule (Erivedge™) are covered.

Update on Drugs and Drug News: April 2011

Update on drugs, approval dates, and comments. Gabapentin tablets GRALISE™(DM-1796), Oxychlorine compound (Epicyn™ HydroGel), Collagenase clostridium histolyticum (XIAPEX®) as well as drug news on HPV vaccines.

Update on Drugs & Drug News, November 2005

Updates on: Desloratadine CLARINEX® REDITABS® Dapsone ACZONE™ Gel 5% Metronidazole Metrogel® Topical Gel 1% Measles, Mumps, Rubella and Varicella Vaccine Proquad®

Body Piercing: More Than Skin Deep

Young adult populations (18-25 years of age) throughout the world have latched onto the mainstream trend of body piercing. Best health care practices for these individuals involves the knowledge of proper procedural techniques, postsite care, common complications, and treatment modalities.

Update on Drugs and Drug News – May 2007

Update on Antiacne Agent Drospirenone/ Ethinyl Estradiol Yaz® Berlex, Corticosteroid Clobetasol Propionate 0.05% Olux-E™ Foam Stiefel Laboratories and news from US FDA.

Update on Drugs and Drug News – March 2006

Update on Calcipotriene/Betamethasone Dipropionate OintmentTaclonex® Warner Chilcott/LEO Pharma, Etanercept Enbrel® Amgen/Wyeth Pharmaceuticals, and drug news about Updated Labeling, Dear Doctor Letter and Cleansing Agents.

Treatments for Pityriasis Rosea

Pityriasis rosea is a common skin disorder in children and young adults. It is a self-limiting disease with symptoms that are typically mild and tolerable, however, there are times when treatment is warranted. In this paper, we review the available treatments for this skin disease.

Allergic Contact Dermatitis in Children: A Practical Approach to Management

Allergic contact dermatitis (ACD) may account for at least 20% of all childhood dermatitis. Clinically, its morphology is identical to other forms of dermatitis in acute, subacute and chronic forms. A persistent or unusual and localized pattern is often the key to diagnosis.

POPULAR

Advertisement